PeproTech IGFBP5 Polyclonal Antibody, PeproTech®, Invitrogen™

Catalog No.	Quantity
500P23250UG	50 μg
500P232100	100 μg
500P2321MG	1 mg

Catalog No. 500P23250UG Supplier PeproTech Supplier No. 500P23250UG

Description

Rabbit Polyclonal Antibody

AA Sequence of recombinant protein: MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IGF-BP5. Anti-Human IGF-BP5-specific antibody was purified by affinity chromatography employing an immobilized Human IGF-BP5 matrix. Sandwich ELISA: To detect Human IGF-BP5 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IGF-BP5 (500-P232Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human IGF-BP5. Western Blot: To detect Human IGF-BP5 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human IGF-BP5 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

The insulin-like growth factor-binding proteins, or IGFBPs, are a family of homologous proteins that have co-evolved with the IGFs. They serve not only as shuttle molecules for the soluble IGFs, but also confer a level of regulation to the IGF signaling system. Physical association of the IGFBPs with IGF influences the bio-availability of the growth factors, as well as their concentration and distribution in the extracellular environment. In addition, the IGFBPs appear to have biological activity independent of the IGFs. Seven IGFBPs have thus far been described, each differing in their tissue distribution, half-lives and modulation of IGF interactions with their receptors. For instance, IGFBP1 is negatively regulated by insulin production. The IGFBP1 gene is expressed at a high level during fetal liver development and in response to nutritional changes and diabetes. It has been suggested that IGFBP2 functions as chaperone, escorting IGFs to their target tissues. It is expressed in several human tissues including fetal eye and fetal brain. IGFBP3 is the most abundant IGFBP and is complexed with roughly 80% of the serum IGFs. Both IGFBP3 and IGFBP4 are released by dermal fibroblasts in response to incision injury. IGFBP5 is secreted by myoblasts and may play a key role in muscle differentiation.

Specifications

• Antigen: IGFBP5
• Applications: ELISA, Western Blot
• Classification: Polyclonal
• Concentration: 0.1-1.0 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative
• Gene: IGFBP5
• Gene Accession No.: P24593
• Gene Alias: AI256729; AW208790; IBP 5; IBP5; IBP-5; IGF BP5; IGF-binding protein 5; IGFBP; IGFBP 5; Igfbp5; IGF-BP5; Igfbp-5; IGFBP-5P; Insulin like growth factor binding protein; insulin like growth factor binding protein 5; insulin-like growth factor binding protein 5; insulin-like growth factor binding protein-5; insulin-like growth factor-binding protein 5
• Gene Symbols: IGFBP5
• Host Species: Rabbit
• Immunogen: E.coli-derived Recombinant Human IGF-BP5.
• Purification Method: Antigen affinity chromatography
• Quantity: 50 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 3488
• Target Species: Human
• Content And Storage: -20°C
• Product Type: Antibody
• Form: Lyophilized